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Abstract
This 9th Symposium on Hemostasis is an international scientific meeting held biannu-
ally in Chapel Hill, North Carolina. The meeting is in large measure the result of the 
close friendship between the late Dr. Harold R. Roberts of UNC Chapel Hill and Dr. 
Ulla Hedner of Novo Nordisk. When Novo Nordisk was developing the hemophilia 
therapy that would become NovoSeven, they sponsored a series of meetings to un-
derstand the basic biology and clinical applications of factor VIIa. The first meeting in 
Chapel Hill was held April 4- 6, 2002 with Dr. Roberts as the organizer. Over the years, 
the conference emphasis has expanded from discussions of factor VIIa and tissue fac-
tor to additional topics in hemostasis and thrombosis. This year’s meeting includes 
presentations by internationally renowned speakers that discuss the state- of- the- art 
on an array of important topics, including von Willebrand factor, engineering ad-
vances, coagulation and disease, tissue factor biology, therapeutic advances, and 
basic clotting factor biology. Included in this review article are illustrated abstracts 
provided by our speakers, which highlight the main conclusions of each invited talk. 
This will be the first meeting without Dr. Roberts in attendance, yet his commitment 
to excellent science and his focus on turning science to patient care are pervasively 
reflected in the presentations by our speakers.
[Article updated on July 4, 2018, after first online publication on April 12, 2018: References were renumbered for indexing purposes.]
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PAR2 in viral infections
Silvio Antoniak PhD
There is a known interaction between the blood coagulation and innate immune system partly mediated by protease- 
activated receptors (PARs).1 During viral infection, pathogen and host- derived proteases including known PAR2 activators 
are generated. Importantly, we and others showed that PAR2 dampens antiviral interferon β (IFNβ) but increases NFκB 
responses after viral infections.1–3 In viral myocarditis, cardiac PAR2 inhibits IFNβ responses during Coxsackievirus B3 
virus infection causing increased cardiac virus load and inflammation and subsequently increased cardiac injury.2 In addi-
tion, we and others found that PAR2 increases H1N1 influenza A virus (IAV) pathology.3 Recent findings suggest that my-
eloid cell (possibly macrophage) and lung epithelial cell PAR2 contribute to IAV pathology. Preliminary data showed that 
PAR2 activation leads to increased CXCL1 expression and neutrophil infiltration into the lung and subsequently causing 
endothelial cell (EC) and epithelial cell (EPC) injury. The current data suggest a potential therapeutic strategy by blocking 
the pathologic PAR2 signaling pathway to improve the outcome and severity of virus infections.
1.  Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood. 2014;123:2605–13.
2.  Weithauser A, Bobbert P, Antoniak S, et al. Protease- activated receptor 2 regulates the innate immune response to viral infection in a CVB3- induced 
myocarditis. J Am Coll Cardiol. 2013;62:1737–45.
3.  Nhu QM, Shirey K, Teijaro JR, et al. Novel signaling interactions between proteinase- activated receptor 2 and Toll- like receptors in vitro and in vivo. 
Mucosal Immunol. 2010;3:29–39.
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Polyphosphate complements coagulation
Edward M. Conway MD, PhD
In response to injury, platelets (plts) and endothelial cells (ECs) are activated, causing polyphopshate (polyP) and C1- esterase 
inhibitor (C1- INH) to colocalize on the cells. PolyP triggers coagulation via activation of factors XII and XI to XIIa and XIa, re-
spectively (1a), leading to thrombin (IIa) generation and clot formation4 (1b). XIIa also converts prekallirein (PK) to kallikrein (K), 
which yields more XIIa and bXIIa.
Activated platelets and endothelial cells also trigger complement activation (2a), promoting assembly of C3 and C5 con-
vertases, which lead to formation of C5b,6 and the C5b- 9 membrane attack complex (MAC). bFXIIa also contributes by activat-
ing complement factors C1r and C1s (2b).
If unchecked, complement activation results in autoimmune destruction of the activated endothelial cells and platelets, ab-
rogating their procoagulant functions. PolyP prevents this by potentiating the inhibitory properties of C1- INH, such that it 
neutralizes C1r and C1s (3a), and destabilizes C5b,66 (3b), reducing MAC formation.
4.  Morrissey JH, Smith SA. Polyphosphate as modulator of hemostasis, thrombosis, and inflammation. J Thromb Haemost. 2015;13(Suppl 1):S92–7.
5.  Wijeyewickrema LC, Lameignere E, Hor L, et al. Polyphosphate is a novel cofactor for regulation of complement by the serpin C1- inhibitor. Blood. 
2016;128:1766–76.
6.  Wat J, Foley JH, Krisinger MK, et al. Polyphosphate suppresses complement via the terminal pathway. Blood. 2014;123:768–76.
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Von Willebrand disease type 2B: an ever surprising condition
Cécile V. Denis PhD
Von Willebrand disease type 2B (vWD- type 2B) is a counterintuitive pathological condition in which gain- of- function mutations 
in the plasma protein von Willebrand factor (VWF) lead to a bleeding rather than a prothrombotic phenotype. For the most 
severe mutations, underlying molecular mechanisms involve: (1) defective platelet function due to impaired signaling leading to 
lack of activation of αIIbβ3 integrin7 and (2) thrombocytopenia of various severity. This thrombocytopenia originates from a 
central production defect8 as well as from an increased clearance of platelets from the circulation.9 How mutations in VWF can 
induce such a variety of cellular effects is currently under investigation. Interestingly, strategies aiming to restore a normal 
platelet count such as thrombopoietin receptor agonists or LIM kinase inhibitors may be beneficial in some patients with vWD- 
type 2B.
7.  Casari C, Berrou E, Lebret M, et al. Von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin alphaIIbbeta3. J Clin Invest. 
2013;123:5071–81.
8.  Kauskot A, Poirault- Chassac S, Adam F, et al. LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease- 
type 2B. JCI Insight. 2016;1:e88643.
9.  Casari C, Du V, Wu YP, et al. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B- associated thrombocy-
topenia. Blood. 2013;122:2893–902.
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Novel hemophilia therapeutics
Lindsey A. George MD
Novel therapeutics for hemophilia are poised to alter the current treatment paradigm. Traditional factor- replacement has normalized 
the life expectancy of hemophilia patients. However, several aspects remain suboptimal, including the need for recurrent intrave-
nous administration and thus significant planning, and the risk of alloantibody formation. Current novel therapeutics include success-
ful early- phase adeno- associated virus- mediated factor VIII and IX gene transfer, a FVIII- mimetic antibody (emicizumab) and 
strategies to disrupt natural anticoagulants, including tissue factor pathway inhibitory (TFPI) antibodies, an activated protein C (APC) 
serpin, and RNAi knock- down of antithrombin III (ATIII) with fitusiran.10–15 Importantly, these new agents can be administered sub-
cutaneously and/or at a reduced frequency. However, thrombotic complications and deaths reported in clinical trials with emici-
zumab and fitusiran highlight the importance of bridging science with clinical care to ensure safe adaptation. Nonetheless, this 
expanding therapeutic repertoire provides an optimistic outlook for the future of hemophilia care.
10.  Rangarajan S, Walsh L, Lester W, et al. AAV5- factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377:2519–30.
11.  George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high- specific- activity factor IX variant. N Engl J Med. 2017;377:2215–27.
12.  Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting antithrombin in hemophilia A and B with RNAi therapy. N Engl J Med. 2017;377:819–28.
13.  Polderdijk SG, Adams TE, Ivanciu L, et al. Design and characterization of an APC- specific serpin for the treatment of hemophilia. Blood. 
2017;129:105–13.
14.  Waters EK, Sigh J, Friedrich U, et al. Concizumab, an anti- tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma 
from haemophilia patients and healthy subjects measured by the thrombin generation assay. Haemophilia. 2017;23:769–76.
15.  Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809–18.
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Cross- talk of insulin and aPC signaling in the kidney
Berend Isermann MD
Insulin resistance and diabetes mellitus are associated with impaired renal function. Expression of the insulin receptor in the 
kidney is established,16 but the mechanism through which insulin resistance contributes to diabetic nephropathy remains un-
known. We demonstrated that insulin signaling (1) induces dissociation of the regulatory p85- subunits from the endoplasmic 
reticulum (ER)- dependent transcription factor spliced XBP- 1 (sXBP1, 2), promoting its nuclear translocation (3).17 This effect, 
which conveys protective aspects of ER- signaling, is lost in insulin resistance, promoting diabetic nephropathy. Activated pro-
tein C (aPC) signaling (4) via protease activated receptors 1 and 3 (PAR1/3) restores sXBP1- p85 dissociation (2) and sXBP1nu-
clear translocation (3), maintaining kidney function.18 In vivo, aPC restores ER- function and protects mice lacking the insulin 
receptor from aggravated diabetic nephropathy. This unravels a new function of coagulation proteases, compensating for de-
fective insulin signaling, and alludes to new therapeutic options in diabetic nephropathy.
16.  Lay A, Coward RJ. Recent advances in our understanding of insulin signalling to the podocyte. Nephrol Dial Transplant. 2014:29;1127–33.
17.  Madhusudhan T, Wang H, Dong W, et al. Defective podocyte insulin signalling through p85- XBP1 promotes ATF6- dependent maladaptive ER- 
stress response in diabetic nephropathy. Nat Commun. 2015;6:6496.
18.  Madhusudhan T, Wang H, Ghosh S, et al. Signal integration at the PI3K- p85- XBP1 hub endows coagulation protease activated protein C with insu-
lin like function. Blood. 2017;130:1445–55.
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Cellular products and contact activation
Nigel S. Key MD
Cell damage and/or death occur during several pathological processes that are associated with an increased risk of thrombosis. 
Neutrophil extracellular traps (NETs), which are composed of a backbone of chromatin, can be expelled by activated neutrophils 
(1). NETs can be degraded into their component molecular structures including nucleosomes, histone octamers, single histones 
and/or free DNA (2). Incubation of single histones (H3 and H4) with platelets or red blood cells (RBCs) induces microvesicle (MV) 
release from both of these cell types (3). Platelet- and RBC- derived MVs are also generated in red cell and platelet units for 
transfusion during blood bank storage (4). RBC- MVs and PLT- MVs activate the contact system (5). Unlike histones, nucleosomes 
or intact NETs, free DNA directly triggers contact activation (6). The activated form of factor XII (FXIIa) is generated following 
contact activation. FXIIa may promote activation of factor XI (7), which mediates downstream thrombin generation (8).
19.  Noubouossie DF, Whelihan MF, Yu YB, et al. In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil 
extracellular traps. Blood. 2017;129:1021–9.
20.  Mooberry MJ, Bradford R, Hobl EL, Lin FC, Jilma B, Key NS. Procoagulant microparticles promote coagulation in a factor XI- dependent manner in 
human endotoxemia. J Thromb Haemost. 2016;14:1031–42.
     |  415ILLUSTRATED REVIEW
Specificity and function in thrombin and the products of 
prothrombin activation
Sriram Krishnaswamy PhD
The cleavage of prothrombin to thrombin is required for fibrin formation and platelet activation. Thrombin also plays both posi-
tive and negative regulatory roles in coagulation because of its pan- specific action on multiple coagulation proteins. These 
different, and sometimes opposing functions arise from the binding of ligands and substrates to two exosites (ABE1 and ABE2) 
on the proteinase. Thrombin employs ABE1 to act on numerous substrates and to bind different ligands. The authentic protein 
ligand for ABE2 is the N- terminal propiece of prothrombin released upon thrombin formation or covalently retained in the in-
termediate, meizothrombin.21 Competitive binding interactions between common ligands for any one exosite and reciprocal 
allosteric effects of ligand binding to the two exosites differentially impact the range of thrombin functions.22,23 Both exosite 
binding and allosteric transitions, arising from these binding steps, regulate the essential roles played by thrombin and its pre-
cursors in coagulation.
21.  Bradford HN, Krishnaswamy S. Meizothrombin is an unexpectedly zymogen- like variant of thrombin. J Biol Chem. 2012;287:30414–25.
22.  Krishnaswamy S. The transition of prothrombin to thrombin. J Thromb Haemost. 2013;11(Suppl 1):265–76.
23.  Kamath P, Huntington JA, Krishnaswamy S. Ligand binding shuttles thrombin along a continuum of zymogen- and proteinase- like states. J Biol 
Chem. 2010;285:28651–8.
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Next generation microfluidic devices to investigate hemostasis
Wilbur A. Lam MD, PhD
Research from the last decade has demonstrated microfluidic devices, which are developed from microchip- based technolo-
gies, to be ideal tools for quantitatively analyzing clot formation, typically in a thrombotic context.24,25 More recently, several 
groups including our own have begun developing microfluidic systems that model bleeding and function as quantitative 
research- enabling tools to study the hemostatic process in vitro. These next generation microfluidic devices recapitulate physi-
ologic biological, biochemical, and/or biophysical aspects of hemostasis that existing in vitro assays are incapable of. For exam-
ple, a microfluidic bleeding model comprising an “endothelialized” microchannel coupled with a microengineered pneumatic 
valve that induces a mechanical vascular “injury” allows for visualization of hemostatic plug formation and measurement of an 
“in vitro bleeding time” (Section A). In addition, high- throughput contractile force measurements of individual platelets enabled 
by microfluidic platelet contraction cytometry may serve as a new platelet function test for platelet- based bleeding disorders 
(Section B).26
24.  Tsai M, Kita A, Leach J, et al. In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic 
technology. J Clin Invest. 2012;122:408–18.
25.  Ciciliano JC, Sakurai Y, Myers DR, et al. Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary 
microfluidic approach. Blood. 2015;126:817–24.
26.  Myers DR, Qiu Y, Fay ME, et al. Single- platelet nanomechanics measured by high- throughput cytometry. Nature Mater. 2017;16:230–35.
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Factor VIII and von Willebrand factor: a complex relationship
David Lillicrap MD
Deficiencies or dysfunction of the procoagulant cofactor, factor VIII (FVIII), or the adhesive protein, von Willebrand factor 
(VWF), represent the most common inherited bleeding disorders in humans. These proteins have inter- related life cycles and 
circulate in the plasma in a tight noncovalent complex.27 VWF plays a dominant role in this interaction. After many years of 
debate, it appears that both proteins are synthesized predominantly in endothelial cells, although the subtypes of endothelium 
that are involved and the fact that most cells express only one of the two proteins are features that require more study.28 In the 
plasma, VWF protects FVIII from premature proteolytic cleavage by activated protein C and acts to guide FVIII to the site of 
vessel wall damage. Ultimately, both FVIII and VWF are cleared from the circulation by macrophages, hepatocytes and sinusoi-
dal endothelial cells in the spleen and liver through interactions involving several lectin and scavenger receptors.29
27.  Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII- VWF association and its clinical 
implications for hemophilia A. Blood. 2016;128:2007–16.
28.  Pan J, Dinh TT, Rajaraman A, et al. Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo. Blood. 
2016;128:104–9.
29.  Lenting PJ, Pegon JN, Christophe OD, Denis C V. Factor VIII and von Willebrand factor—too sweet for their own good. Haemophilia. 2010;16(Suppl 5): 
194–9.
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Developing an enzyme- based approach to prepare synthetic 
low- molecular- weight heparin
Jian Liu PhD
Low- molecular- weight heparin (LMWH) is clinically used to treat clotting disorders. As an animal- sourced product, LMWH’s 
supply chain reliability is a concern for regulatory agencies. Here, we demonstrate the synthesis of heparin dodecasaccharides 
(12- mers) at gram- scale. In vitro and ex vivo experiments demonstrate that the anticoagulant activity of the 12- mers could be 
reversed using protamine. The 12- mer reduced the size of blood clot in the mouse model of deep vein thrombosis, and attenu-
ated the procoagulant markers in the mouse model of sickle- cell disease. The 12- mer was examined in a nonhuman primate 
model to determine the pharmacodynamics parameters. A 7- day toxicity study in a rat model showed no toxic effects. The data 
suggest that a synthetic homogeneous oligosaccharide can replace animal- sourced LMWHs.
30.  Xu Y, Chandarajoti K, Zhang X, et al. Synthetic oligosaccharides can replace animal- sourced low- molecular weight heparins. Sci Transl Med. 
2017;9:eaan5954.
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Platelet biogenesis in the lung circulation
Mark R. Looney MD
Platelets are indispensable in hemostasis, thrombosis, and immune responses. In humans, billions of platelets are produced each 
day from megakaryocytes, however the mechanisms of mature platelet production are incompletely understood. Historical 
data indicate that the lung may be a site of platelet biogenesis. Using intravital imaging in mice,31 megakaryocytes were visual-
ized releasing platelets in the lung circulation, and this process was responsible for approximately half of the mature platelet 
production in mice.32 The mechanisms by which the lung circulation facilitates platelet biogenesis is a novel area of investigation 
for understanding platelet production defects. The lung may be a suitable bioreactor for the production of mature platelets 
from in vitro- derived megakaryocytes.33 The lung also contains “resident” megakaryocytes and hematopoietic precursors, the 
latter being capable of migrating to the bone marrow to participate in the production of platelets and other mature hematopoi-
etic lineages.
31.  Looney MR, Thornton EE, Sen D, Lamm WJ, Glenny RW, Krummel MF. Stabilized imaging of immune surveillance in the mouse lung. Nat Methods. 
2011;8:91–6.
32.  Lefrançais E, Ortiz- Muñoz G, Caudrillier A, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 
2017;544:105–9.
33.  Wang Y, Hayes V, Jarocha D, et al. Comparative analysis of human ex vivo- generated platelets vs megakaryocyte- generated platelets in mice: a 
cautionary tale. Blood. 2015;125:3627–36.
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Regulation of von Willebrand factor function at the level of 
self- association
José A. López MD
Von Willebrand factor is the largest protein in blood plasma and has multiple roles in hemostasis, the best known of which is to 
mediate the attachment of platelets to the vessel wall, usually at sites of injury. In pathological states, VWF can remain attached 
to the vessel wall and allow platelets to attach to intact vascular endothelium. The ability of VWF to carry out its adhesive func-
tion is regulated by a number of factors, including the concentration of the protein, its mutimeric structure, and the degree to 
which it is proteolyzed by the plasma protease ADAMTS13. Less appreciated as important for VWF function is its ability to 
self−associate,	 taking	 already	 very	 long	 molecules	 and	 assembling	 them	 into	 strands	 of	 potentially	 prodigious	 sizes	 (see	
Figure).34,35 VWF self- association is itself regulated by a variety of factors, including concentration, shear stress and elonga-
tional flow/proteolysis, and high density lipoproteins.36
34.  Dong JF, Moake JL, Nolasco L, et al. ADAMTS- 13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial 
surface under flowing conditions. Blood. 2002;100:4033–9.
35.  Zheng Y, Chen J, Lopez JA. Flow- driven assembly of VWF fibres and webs in in vitro microvessels. Nat Commun. 2015;6:7858.
36.  Chung DW, Chen J, Ling M, et al. High- density lipoprotein modulates thrombosis by preventing von Willebrand factor self- association and subse-
quent platelet adhesion. Blood. 2016;127:637–45.
Factors influencing VWF self-association:
0 elevated shear stress and elongational flow
0 plasma VWF concentration
0 high-density lipoprotein
0 low-density lipoprotein
Direction of Blood Flow
ULVWF Strands
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Platelet polyphosphate and factor XII (nature’s way to engineer 
nanoparticles)
Coen Maas PhD
The contact system contributes to coagulation in vitro, but contact factor deficiencies do not cause bleeding. Remarkably, the 
contact system has a pronounced role in mouse thrombosis models. Here, platelet polyphosphate was proposed as the endog-
enous trigger for Factor XII (FXII) activation.37,38 This is surprising as short platelet polyphosphate polymers have limited poten-
tial for contact activation.
Contact system activators in clotting reagents are usually fine particulates. We found that platelets store and release 
polyphosphate in a comparable state as polyphosphate nanoparticles, which can be tracked with DAPI (membrane- permeant) 
and SYTOX (membrane- impermeant).39 Polyphosphate nanoparticles remain on the platelet surface under flow, and can be 
isolated from platelet lysates. Platelet- sized polyphosphate efficiently triggers contact system activation as a nanoparticle state, 
but much less as a soluble polymer.
Extracellular polyphosphate is concentrated in the core of the thrombus, but not in the shell. This favors the concept that the 
contact system contributes to thrombus stability: once a thrombus is physically “threatened” and plasma reaches the thrombus 
core, FXII- driven thrombin formation is triggered to ensure thrombus stability.
37.  Labberton L, Kenne E, Long AT, et al. Neutralizing blood- borne polyphosphate in vivo provides safe thromboprotection. Nat Commun. 2016;7:12616.
38.  Travers RJ, Shenoi RA, Kalathottukaren MT, Kizhakkedathu JN, Morrissey JH. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing 
hemostasis. Blood. 2014;124:3183–90.
39.  Verhoef JJFF, Barendrecht AD, Nickel KF, et al. Polyphosphate nanoparticles on the platelet surface trigger contact system activation. Blood. 
2017;129:1707–17.
FXII
FXII
A
SYTOX
DAPI
Platelet
Ca2+
Ca2+ Ca2+ Ca2+
Ca2+
Ca2+
FLOW
Collagen
Ca2+
H+H+
H+
o
- - - - - - - - - - - -
--
----
--
oo o o o
oPPPPP P o
oo
o
oo
oo
oo
oo
II
I I I I I I
II II II II II
Dense granule
Rele
ase
422  |     ILLUSTRATED REVIEW
New treatment options in TTP
Flora Peyvandi MD, PhD
Thrombotic thrombocytopenic purpura (TTP) is a rare, acute- onset disease caused by the congenital or acquired deficiency of 
ADAMTS13, leading to microvascular thrombosis and ischemic organ damage. The mainstays of acute TTP treatment are plasma 
infusion (hereditary TTP) and plasma- exchange in conjunction with immunosuppressive therapy (acquired TTP). Despite a dra-
matic improvement in TTP diagnosis and treatment, mortality (10%), exacerbation (30%), major thrombotic complications, re-
fractoriness to standard therapy and long- term complications are still major issues demanding novel therapies. Recombinant 
ADAMTS1340 and caplacizumab,41,42 a nanobody against the platelet- binding domain of VWF, recently completed phase I (clini-
caltrials.gov NCT02216084) and III (HERCULES trial, clinicaltrials.gov NCT02553317) clinical trials for the treatment of heredi-
tary and acquired TTP, respectively. Recombinant ADAMTS13 was safe, well- tolerated, with pharmacokinetic parameters 
comparable with those from plasma infusion studies.40 Caplacizumab met primary and key secondary endpoints in HERCULES 
trial,42 confirming previous phase II results from the TITAN trial.41
40.  Scully M, KnÖbl P, Kentouche K, et al. Recombinant ADAMTS- 13: first- in- human pharmacokinetics and safety. Blood. 2017;130:2055–63.
41.  Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374:511–22.
42.  Scully M, Cataland S, Peyvandi F, et al. Results of the randomized, double- blind, placebo- controlled, phase 3 Hercules study of caplacizumab in 
patients with acquired thrombotic thrombocytopenic purpura. Blood. 2017;130(Suppl 1):LBA- 1.
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TF control of PAR2 signaling
Wolfram Ruf MD
Protease activated receptor (PAR) 2 is the target for upstream coagulation proteases, FVIIa and FXa, and cleaved during TF- 
initiated coagulation. We have identified crucial residues in the FVIIa protease domain that regulate ligand binding and thereby 
direct the biological functions of the TF- FVIIa complex in hemostasis and cell signaling. The integrin binding motif (KGE) residue 
FVII E26 promotes TF- FVIIa complex formation with active integrin β1 and couples TF to integrin- arf6 recycling required for 
endosomal pro- angiogenic and pro- migratory PAR2 signaling43. In the same region of the FVIIa protease domain, the allosteric 
switch residue FVIIa E154 controls the release of nascent FXa product required for TF prothrombotic activity. In contrast, stabil-
ity of the TF- FVIIa- FXa ternary complex favors hemostatic cofactor FVIII activation44 and EPCR- dependent cleavage of PAR2 
by FXa that is crucial for toll- like receptor (Tlr) 4 innate immune signaling, specifically the induction of interferon- regulated 
genes45. Mutants of PAR2 with resistance to selective coagulation proteases and cell type- specific coagulation factor deficien-
cies begin to delineate the distinct contributions of TF signaling complexes in the regulation of immune responses and cancer 
progression.
43.  Rothmeier AS, Liu E, Chakrabarty S, et al. Identification of the integrin- binding site on coagulation factor VIIa required for pro- angiogenic PAR2 
signaling. Blood. 2018;131:674–85.
44.  Kamikubo Y, Mendolicchio GL, Zampolli A, et al. Novel factor VIII activation mechanism by the tissue factor- factor VIIa- factor Xa complex. Blood. 
2017;130:1661–70.
45.  Liang HPH, Kerschen EJ, Hernandez I, et al. EPCR- dependent PAR2 activation by the blood coagulation initiation complex regulates LPS- triggered 
interferon responses in mice. Blood. 2015;125:2845–54.
424  |     ILLUSTRATED REVIEW
The platelet lifeline to cancer
Anil K. Sood MD
Platelets are well known to play important roles in hemostasis and wound remodeling and healing. However, the bidirectional 
interplay between platelets and cancer is increasingly recognized for its impact on tumor biology and patient outcomes. 
Thrombocytosis, resulting from tumor- derived factors, occurs with varying frequency in cancer patients and is associated with 
adverse clinical outcomes.46 Biologically, cancer is often considered analogous to a non- healing or chromic wound. There is 
growing evidence that platelets play key roles in many steps of tumor development and progression including proliferation, 
extravasation, survival, and metastasis.47 Moreover, platelets may actively infiltrate into the tumor microenvironment and facili-
tate evasion from cancer therapies.48 Understanding these complex interactions related to the roles of platelets in tumor biol-
ogy offer new opportunities for reducing thrombosis, blocking tumor growth, and ultimately improving patient outcomes.
46.  Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366:610–18.
47.  Haemmerle M, Bottsford- Miller J, Pradeep S, et al. Platelet FAK is a critical regulator of tumor growth after withdrawal of anti- angiogenic therapy. 
J Clin Invest. 2016;126:1885–96.
48.  Haemmerle M, Taylor ML, Gutschner T, et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 
2017;8:310.
49. Tumor cell interactions with platelets and other circulating factors (with permission from Menter DG, et al., Cancer Metastasis Rev. 2014;33:231–69).
     |  425ILLUSTRATED REVIEW
TF and cancer: blocking tissue factor signaling in breast cancer 
inhibits tumor metastasis
Henri H. Versteeg PhD
Tissue factor (TF) promotes breast cancer metastasis by activating coagulant pathways,50,51 but the role of TF signaling in me-
tastasis has never been addressed. We show that an antibody against TF that inhibits signaling uncouples TF from integrin a3b1 
and leads to a net cellular increase in active integrin b1. In vitro, TF inhibition leads to a reduction in cancer stem cells (CSCs) 
and CSC effector molecules such as Sox9 and Slug. Such a link between TF and CSC is supported by an association between TF 
expression and the CSC marker aldehyde dehydrogenase 1 (ALDH1) in tumor specimens from 574 breast cancer patients. In 
vivo we show that inhibition of TF signaling inhibits metastasis 10- fold when given in a scheme that has little effect on primary 
tumor growth. Thus, TF signaling inhibition leads to a reduced CSC transcriptional program, a reduction in primary tumor- 
resident cancer stem cells and a subsequent reduction in metastasis.
50.  Van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and 
bedside. Blood. 2012;119:924–32.
51.  Palumbo JS, Talmage KE, Massari JV, et al. Tumor cell- associated tissue factor and circulating hemostatic factors cooperate to increase metastatic 
potential through natural killer cell- dependent and- independent mechanisms. Blood. 2007;110:133–41.
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Fibrinogen and factor XIII in venous thrombosis
Alisa S. Wolberg PhD
Venous thrombosis is a leading cause of death and disability worldwide. Venous thrombi typically originate in hypoxic venous 
valve pockets and areas of reduced blood flow (stasis), where activated endothelium expresses cell adhesion molecules that 
engage leukocytes at the vessel wall (1). Procoagulant endothelium and leukocytes support thrombin (IIa) generation (2), which 
leads to conversion of fibrinogen to fibrin and formation of a fibrin network that entraps red blood cells (RBCs) (3). Thrombin 
also converts factor XIII (FXIII) to an active transglutaminase (FXIIIa) (4), which crosslinks fibrin and also crosslinks plasma pro-
teins to fibrin. Crosslinked fibrin retains RBCs in clots during platelet- mediated clot contraction (5),52,53 and crosslinked α2- 
antiplasmin increases clot resistance to fibrinolysis. Although FXIII is found in both cells and plasma, plasma FXIII is the major 
contributor to fibrin crosslinking and RBC retention, and mediates thrombus size in a dose- dependent manner.54 FXIII(a) may be 
a therapeutic target for reducing venous thrombosis.
52. Aleman MM, Byrnes JR, Wang J- G, et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest. 2014;124:3590–600.
53.  Byrnes JR, Duval C, Wang Y, et al. Factor XIIIa- dependent retention of red blood cells in clots is mediated by fibrin alpha- chain crosslinking. Blood. 
2015;126:1940–48.
54.  Kattula S, Byrnes JR, Martin SM, Cooley BC, Flick MJ, Wolberg AS. Plasma- , but not platelet- factor XIII promotes red blood cell retention in con-
tracted clots and mediates clot size during venous thrombosis. Blood Adv. 2017;2:25–35.
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Thrombin receptor PAR4: new target for antiplatelet therapy
Pancras C. Wong PhD
Thrombin is a potent agonist that induces platelet aggregation via the G- protein coupled protease- activated receptors (PAR), 
PAR1 and PAR4.55 PAR1 is a target of antiplatelet therapy in the clinic, but PAR1 inhibitors have a narrow therapeutic window 
when given on top of standard- of- care antiplatelet agents. We hypothesized that initial platelet responses to low thrombin 
concentrations, mediated by PAR1, are important for hemostasis, whereas sustained platelet responses to high thrombin con-
centrations, mediated by PAR4, are critical for thrombus propagation and thrombosis. To validate PAR4 as a safer antiplatelet 
drug target, we developed the highly selective small- molecule compound inhibitor of PAR4, BMS- 986120. BMS- 986120 is an 
orally- active drug with strong antithrombotic activity and low bleeding liability in cynomolgus monkeys. It demonstrates a 
wider therapeutic window than the standard antiplatelet agent clopidogrel. These preclinical findings suggest that PAR4 is an 
effective and safe antiplatelet drug target.56
55.  Coughlin SR. Thrombin signalling and protease- activated receptors. Nature. 2000;407:258–64.
56.  Wong PC, Seiffert D, Bird JE, et al. Blockade of protease- activated receptor- 4 (PAR4) provides robust antithrombotic activity with low bleeding. 
Sci Transl Med. 2017;9:eaaf5294.
57.  Gachet C. Regulation of platelet functions by P2 receptors. Ann Rev Pharmacol Toxicol. 2006;46:277–300.
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Tissue factor- independent inhibition of thrombin generation by 
TFPIα
Jeremy P. Wood PhD
The tissue factor (TF) pathway of thrombin generation, which commences when the TF/factor VIIa (FVIIa) complex activates 
the serine protease factor Xa (FXa), is inhibited by TF pathway inhibitor alpha (TFPIα) at three steps. First, two inhibitory do-
mains of TFPIα (K1, K2) block FXa activation by TF/FVIIa. Second, TFPIα also inhibits the generated FXa by blocking its active 
site with K2. The cofactor protein S promotes and stabilizes this interaction.58 Third, TFPIα inhibits prothrombinase, the 
thrombin- producing complex of FXa and factor Va (FVa), during the initiation of thrombin generation.59 This inhibition requires 
that K2 binds the FXa active site and that the TFPIα basic C- terminus binds both a regulatory acidic region present in FXa- 
activated and platelet- released forms of FVa and the FVa heavy chain, an interaction which displaces FXa.59,60 Through these 
TF- dependent and - independent activities, TFPIα establishes an activation threshold for the initiation of coagulation.
58.  Wood JP, Ellery PE, Maroney SA, Mast AE. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor- alpha but not for cell 
surface- associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2014;34:169–76.
59.  Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE. Tissue factor pathway inhibitor- alpha inhibits prothrombinase during the initi-
ation of blood coagulation. Proc Natl Acad Sci U S A. 2013;110:17838–43.
60.  Wood JP, Petersen HH, Yu B, Wu X, Hilden I, Mast AE. TFPIalpha interacts with FVa and FXa to inhibit prothrombinase during the initiation of 
coagulation. Blood Adv. 2017;1:2692–702.
